# Phase 1 Study of ELX-02 in Healthy Adults

> **NCT03292302** · PHASE1 · COMPLETED · sponsor: **Eloxx Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Genetic Disease
- Nonsense Mutation

## Interventions

- **DRUG:** Placebo
- **DRUG:** ELX-02

## Key facts

- **NCT ID:** NCT03292302
- **Lead sponsor:** Eloxx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2017-12-15
- **Final completion:** 2017-12-15
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292302, "Phase 1 Study of ELX-02 in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03292302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*